Seres announces preliminary ser-287 phase 2b eco-reset study microbiome data analysis

Cambridge, mass.--(business wire)--seres therapeutics, inc. (nasdaq: mcrb), a leading microbiome therapeutics company, today announced preliminary microbiome data analyses from the phase 2b eco-reset study evaluating ser-287 in patients with mild-to-moderate ulcerative colitis (uc). following the topline clinical data readout in july, which noted that the ser-287 phase 2b study did not achieve its primary endpoints, analysis of the microbiome data demonstrated the successful engraftment of ser-
MCRB Ratings Summary
MCRB Quant Ranking